Amgen vs. Sanofi: What the Supreme Court Decision Could Mean for Future Pharmaceutical Patents
The Supreme Court recently granted Amgen’s petition for certiorari against the advice of the U.S. government, taking up Amgen’s challenge to the Federal Circuit’s enablement review of its PCSK9 antibody patents covering evolocumab (Repatha®). In its petition, Amgen asserts that the Federal Circuit has gone too far in invalidating its PCSK9 antibody patents by imposing […]